Klisyri Uniunea Europeană - română - EMA (European Medicines Agency)

klisyri

almirall, s.a. - tirbanibulin - keratoză, actinică - antibiotice și medicamente chimioterapeutice de uz dermatologic - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.

Jayempi Uniunea Europeană - română - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - respingerea grefei - imunosupresoare - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Melatonin Neurim Uniunea Europeană - română - EMA (European Medicines Agency)

melatonin neurim

rad neurim pharmaceuticals eec sarl - melatonină - tulburări de inițiere și întreținere a somnului - psiholeptice - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

LENALIDOMIDA TERAPIA 10 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida terapia 10 mg

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

LENALIDOMIDA TERAPIA 15 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lenalidomida terapia 15 mg

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare